The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20171842: Heritage Insurance Holdings, Inc.; NBIC Holdings, Inc.
20171847: Centerbridge Capital Partners III, L.P.; Highmark Health
20171850: The Danny Umansky Revocable Living Trust; Kenneth E. Brown
20171851: The Danny Umansky Revocable Living Trust; William E. Schuiling
20171854: ArcLight Energy Partners Fund VI, L.P.; Mitsubishi Corporation
20171856: V.F. Corporation; Williamson-Dickie Holding Company
20171857: Wolverine Acquisition Holdings, LLC; Jeffrey H. Loria
20171864: Signet Jewelers Ltd.; R2NET Inc.
20171867: Berkshire Fund IX, L.P.; ABRY Senior Equity IV, L.P.
20171869: B&G Foods, Inc.; Back to Nature Foods Company, LLC
20171871: Husky Energy Inc.; Calumet Specialty Products Partners, L.P.
20171877: Michael E. Upchurch; Trilliant Holdings L.P.
20171884: Green Equity Investors Side VII, L.P.; KTG Holdings, LLC
Grifols, S.A., and Talecris Biotherapeutics Holdings Corp., In the Matter of
The FTC required Grifols, S.A., a manufacturer of plasma-derived drugs, to make significant divestitures as part of a settlement allowing Grifols to acquire a leading plasma-derived drug manufacturer, Talecris Biotherapeutics Holdings Corp. It resolves FTC charges that Grifols’ proposed acquisition of Talecris would be anticompetitive and would violate federal antitrust laws. As part of the settlement, Grifols will sell the Talecris fractionation facility in Melville, New York, and Grifols’ plasma collection centers in Mobile, Alabama, and Winston-Salem, North Carolina, to Kedrion S.p.A. Kedrion is a manufacturer of plasma-derived products in Europe and other markets, and will be a new entrant in the U.S. plasma-derived products industry. Grifols also will manufacture three plasma-derived products for Kedrion for several years under a manufacturing agreement. The FTC approved a final order on July 22, 2011.